Amarin Corporation PLC O Webcast Discussion Of Presented Data at American Heart Assocition's 2019 Scientific Sessions Transcript
Greetings. Welcome to the AHA investor discussion conference call. (Operator Instructions) Please note this conference is being recorded.
I would now like to turn the conference over to your host, Elisabeth Schwartz. Thank you. You may begin.
Welcome to today's discussion to explore for our investment community the several important new data sets and analyses related to Vascepa and REDUCE-IT as presented at the 2019 American Heart Association's Scientific Sessions here in Philadelphia.
Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements include, but are not limited to, our current expectations regarding Vascepa clinical data and cost-effectiveness analyses and expectations regarding the application of these data to clinical use, in reimbursement and regulatory settings and to commercial prospects for Vascepa.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |